12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zytiga abiraterone acetate regulatory update

The U.K.'s NICE issued draft guidance recommending Zytiga abiraterone from Johnson & Johnson in combination with prednisone or prednisolone in patients with metastatic, castration-resistant prostate cancer (CRPC) that has progressed on or after docetaxel-containing therapy - the drug's approved indication. NICE reversed...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >